Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Inter-reader variability of imaging biomarkers for therapeutic response in pancreatic ductal adenocarcinoma.
Authors
Jon Stanley Heiselman
Memorial Sloan Kettering Cancer Center, New York, NY
Jon Stanley Heiselman , Natally Horvat , Burcin Agridag-Upcinar , Onur Yildirim , Brett Logan Ecker , Eileen Mary O'Reilly , Jeffrey A. Drebin , Vinod P. Balachandran , T. Peter Kingham , Michael Ian D'Angelica , Kevin Soares , Richard K. G. Do , Maria El Homsi , William R. Jarnagin , Alice Chia-Chi Wei , Jayasree Chakraborty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 700)
DOI
10.1200/JCO.2024.42.3_suppl.700
Abstract #
700
Poster Bd #
N9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2018 Gastrointestinal Cancers Symposium
Quantitative PET-MRI for early treatment response assessment in pancreatic ductal adenocarcinoma.
First Author: Martin Valera Consunji
Poster
2024 ASCO Annual Meeting
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.
First Author: Zachary Rivers
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma.
First Author: Fatemeh Fekrmandi